Angiotensin II induces EMMPRIN expression in THP-1 macrophages via the NF-k{green}B pathway

Regulatory Peptides

Volumn 163, Issue 1-3, 2010, Pages 88-95

  Yang, Li xia ^a   Liu, Hong ^a   Guo, Rui wei ^a   Ye, Jinshan ^a   Wang, Xian mei ^a   Qi, Feng ^a   Guo, Chuan ming ^a   Liang, Xing ^a  

^a KUNMING GENERAL HOSPITAL   (China)

Author keywords

Angiotensin II; EMMPRIN; Matrix metalloproteinase 9; NF k green B; THP 1 macrophages

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CD147 ANTIGEN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRROLIDINE DITHIOCARBAMATE; SMALL INTERFERING RNA; SYNAPTOTAGMIN I;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOTENSIN II; ANTIGENS, CD147; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77953914601     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.04.012     Document Type: Article

References (45)

1. Naghavi M., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108(14):1664-1672.
2. Virmani R., et al. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47(8 Suppl):C13-C18.
3. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104(3):365-372.
4. Lusis A.J. Atherosclerosis. Nature 2000, 407(6801):233-241.
5. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90(3):251-262.
6. Johnson J.L., et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005, 102(43):15575-15580.
7. Zeng B., et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005, 35(6):331-335.
8. Biswas C. Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun 1982, 109(3):1026-1034.
9. Biswas C., et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995, 55(2):434-439.
10. Huet E., et al. Role of emmprin/CD147 in tissue remodeling. Connect Tissue Res 2008, 49(3):175-179.
11. Schmidt R., et al. EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture. Thromb Haemost 2006, 95(1):151-158.
12. Major T.C., et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002, 22(7):1200-1207.
13. Schmidt R., et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008, 102(3):302-309.
14. Huang Z., et al. Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 2008, 374(3):517-521.
15. Si A.I., et al. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. J Cell Biochem 2003, 89(6):1154-1163.
16. Schieffer B., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000, 101(12):1372-1378.
17. Castoldi G., et al. Angiotensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: evidence of a pressure-independent effect. Clin Exp Pharmacol Physiol 2007, 34(3):205-209.
18. Guo R.W., et al. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul Pept 2008, 147(1-3):37-44.
19. Park E.K., et al. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res 2007, 56(1):45-50.
20. Tsuchiya S., et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 1982, 42(4):1530-1536.
21. Zhou J., et al. Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol 2005, 6(1):25.
22. Lowry O.H., et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
23. Dobrovolskaia M.A., Vogel S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002, 4(9):903-914.
24. Ge H., et al. Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma. Vascul Pharmacol 2007, 46(2):114-121.
25. Guo R.W., et al. Angiotensin II induces NF-kappa B activation in HUVEC via the p38MAPK pathway. Peptides 2006, 27(12):3269-3275.
26. Aikawa Y., et al. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 2002, 51(4):188-194.
27. Siwik D.A., et al. EMMPRIN mediates beta-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. J Mol Cell Cardiol 2008, 44(1):210-217.
28. Hagemann T., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175(2):1197-1205.
29. Tang Y., et al. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004, 2(2):73-80.
30. Menashi S., et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 2003, 63(22):7575-7580.
31. Yang Y., et al. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(9):1299-1310.
32. Boye K., et al. Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer 2008, 123(6):1301-1310.
33. Seizer P., et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2009.
34. Quemener C., et al. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007, 67(1):9-15.
35. Wagenaar L.J., et al. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002, 18(12):1331-1339.
36. Kranzhofer R., et al. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999, 257(3):826-828.
37. Costanzo A., et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003, 195(3):402-410.
38. Brasier A.R., Recinos A., Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002, 22(8):1257-1266.
39. Browatzki M. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-B and activator protein 1 in a redox-sensitive manner 2005.
40. Yamashita C., et al. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007, 30(12):1219-1230.
41. Johnson J.L., et al. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 2008, 28(9):1647-1653.
42. Schmidt R., et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006, 113(6):834-841.
43. Kim M.P., Zhou M., Wahl L.M. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005, 78(1):195-201.
44. Johnson J.L., et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006, 113(20):2435-2444.
45. Toole B.P. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003, 54:371-389.